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Background: Information about the treatment approach for patients who suffer left main
(LM) stenosis is limited and treatment option controversial. Aim: To analyze the short and
long term outcomes of patients with LM disease treated with the latest generation drug
eluting stent (DES) by pulling data from the NOBORI 2 and eNOBORI registries.
Methods: NOBORI 2 and eNOBORI are two large, prospective, single-arm, multi-
center, registries that enrolled 3067 and 7750 patients respectively, out of which 62 and
212 had at least 1 lesion treated in the Left Main. All adverse events were adjudicated by
an independent clinical event committee in NOBORI 2, while adjudication in eNOBORI
(including stent thrombosis) is ongoing. The primary endpoint was Target Lesion Failure
(TLF) defined as a composite of cardiac death (CD), target vessel related myocardial
infarction (TV-MI) and target lesion revascularization (TLR).
Results: Patients were 72% male, 6612y old, 34% had diabetes mellitus, 10% renal
failure, 33% prior MI, 34% prior PCI and 25% previous cardiac surgery. In 19.5% of
patients PCI was performed in the course of acute MI. Multiple vessels were treated in
55% of patients (2.51.6 lesions per patients). The lesions were complex (70% B2/C
type), ostial (45%), calcified (46%), contained thrombus (8%) and 16% required
bifurcation treatment. Pre- and post-dilatation were performed in 67% and 44% of lesions
respectively. At 1-month, there were no deaths nor TLR, while there were 4 TV-MI
(1.5%) and one TVR (0.5%). The TLF rate was 1.5%. In the cohort of patients followed
at 3-year, 3 patients suffered a cardiac death (4.8%), 2 had an MI (3.2%), one patient
underwent Re-PCI of LM (1.6%) and 6 patients (9.8%) of other vessels. TLF rate was
14.8%. A total of 93.3% of the patients were angina free. No stent thrombosis occurred
up to 3 years.
Conclusions: Short and long term clinical outcomes of patients with LM disease treated
with Nobori, DES with biodegradable polymer, are very encouraging. Low rate of adverse
events and the absence of stent thrombosis up to 3 years in long term follow-up cohort
suggest that this stent is valuable treatment option for patients with LM disease considered
as candidates for PCI.
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Background: Background: Coronary Artery Bypass Grafting is considered the first
choice of treatment for unprotected left main disease(ULMD) compared to clinical
treatment. Percutaneous treatment with drug eluting stents(DES) is showing to be a safe
and effective alternative. The aim of this single center experience evaluation registry, is to
compare MACE incidence between these two revascularization procedures: in hospital
and late Stroke, myocardial infarction (MI) and target vessel revascularization (TVR).
Methods: Methods: from 11/2003 through 12/2010, 241 consecutive pts. with ULMD,
underwent revascularization treatment being 114 with CABG and 127 with DES.
Results: Results: EuroScore  6 incidence was 32% in CABG group vs 49,5% in the
DES group (p0,005).Technique: CABG group with LIMA to LAD in 80,7%, bilateral
mamary artery bypass 26,3%. 2,84 grafts/PT. DES group with 2,6 stents;PT., 92% with
IVUS guidance. In-hospital outcomes CABG vs DES: Mortality 4,38% vs 1,57%
(p0,19), MI 0,87% vs 0,78%( p0,93), TVR 0,87% vs 0,78%( p 0,93), Stroke 2,6%
vs 0% (p0,06), MACE 6,1% vs 1,57% (p0,06). In CABG group mediastinitis
incidence was 5,2% and reoperation need incidence of 7,8%. Acute and sub-acute in stent
thrombosis in the DES group was 1,57%. Mean late follow up (940 days) showed(CABG
vs DES): Mortality 12,8% vs 8% (p0,22), TVR 10.1% vs 9,6%( p0,89), MACE
19,2% vs 15,2% (p0,41). In stent thrombosis 0,8%.
Conclusions: Conclusion: in this analysis, pts with ULMD treated with DES showed a
trend toward to less incidence of stroke and MACE during in hospital phase compared to
CABG, with late follow-up analysis showing equivalence.
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Background: The distal left main coronary artery disease is a particular form of coronary
disease, still challenging for intervention. The results with regular drug-eluting stents
(DES) are not optimal. The dedicated bifurcation stents are promising solution of this
form of coronary disease.
Methods: Dedicated bifurcation paclitaxel-eluting stent BiOSS® Expert and next
generation sirolymus eluting stent BIOSS LIM (Balton, Poland) were used. This
dedicated bifurcation device consists of two parts with different diameter, connected with
two short bridges. BIOSS is mounted on dedicated bifurcation balloon – Bottle – with
three markers (at both ends and at the mid part – for easy positioning at the level of the
carina). 51 patients (17 from Bulgaria and 34 from Poland) were included and followed
for 12 months into prospective, feasibility and safety assessment registry, with exclusions
criteria STEMI, contraindication for 12 months DAP and lack of informed consent. The
primary end-points of the study are: death, myocardial infarction, in-stent thrombosis and
target lesion revascularization (in-hospital and 1, 3, 6, 12 months after the intervention).
The first wave of registry started in Poland in 2009 and was followed in Bulgaria from
second half of 2010.
Results: The average age of the enrolled patients (71% males) was 6715 years. 80%
had hypertension, and 44% have diabetes – 62% for the Bulgarian group and 30% for the
Polish group. Most of patients enrolled have severe coronary disease –more than 50% had
previous AMI, 60% had previous PCI, 13% were after CABG. All BiOSS stents were
implanted successfully without any periprocedural complication. Side branch stent was
implanted more frequently in Polish group – 24% vs. 12% in Bulgarian Group. The TLR
rate at 12 months was 11% - 5.9% (1/17 in BG) and 17.6 (6/34 in Poland); TVR rate was
equivalent - 17.7% vs. 17.6% respectively. MACE rates differ: 23.5% in Bulgarian group
(because of one possible stent thrombosis and MI during follow-up) and 17.6% (because
of restenosis) in Polish group.
Conclusions: The BiOSS bifurcation dedicated stent is a feasible device with promising
safety and short-term clinical effectiveness/profile in LM bifurcation lesions.
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Background: The aim of this study is to compare the safety, efficacy and durability of
Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), Bioli-
musA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of
patients with left main coronary arteries (LMT) stenosis.
Methods: A prospective analysis of 1127 LMT stenosis (321 SES, 277 PES, 129 ZES-R,
172 BES, 55 ECS, 173 EES) in six high volume Asian centers after successful stenting
in LMT stenosis was performed. The study endpoints were 30 days major adverse cardiac
events (MACE) and 12, 24, 36 and 48 months target lesion revascularization (TLR) and
MACE in those 6 groups.
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patients with LMT stenosis was safe with
low acute complication. Patients treated with BES and EES showed lesser rate of
restenosis compared with ZES-R and ECS.
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